Cargando…

Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation

We report the case of a 37‐year‐old male non‐small cell lung cancer patient with an active epidermal growth factor receptor (EGFR) mutation who received gefitinib as first‐line treatment. After 13.7 months, the patient experienced disease progression and was treated with platinum‐based doublet chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Chong‐Rui, Zhong, Wen‐Zhao, Zhou, Qing, Zhang, Xu‐Chao, Yang, Jin‐Ji, Wu, Yi‐Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2016
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217905/ https://www.ncbi.nlm.nih.gov/pubmed/27801981 http://dx.doi.org/10.1111/1759-7714.12382

Ejemplares similares

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
por: Singh, Charu
Publicado: (2014)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
por: Zhou, Jianya, et al.
Publicado: (2015)

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity
por: Naruo, Yoshimi, et al.
Publicado: (2011)

Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib
por: Xu, Fei, et al.
Publicado: (2012)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
por: Sun, Heng, et al.
Publicado: (2018)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Amylase-Producing Lung Cancer with a Positive Epidermal Growth Factor Receptor Mutation Treated With Gefitinib: A Case Report
por: Minami, Seigo, et al.
Publicado: (2014)

Enhanced gefitinib‐induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia‐mutated kinase inhibition in non‐small‐cell lung cancer cells
por: Misumi, Keizo, et al.
Publicado: (2016)

Fuzheng Kang’ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial
por: Yang, Xiao-Bing, et al.
Publicado: (2015)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
por: Yu, Ruofei, et al.
Publicado: (2021)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation‐positive non‐small cell lung cancer
por: Sun, Hongyan, et al.
Publicado: (2015)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Rad51 in regulating the radiosensitivity of non‐small cell lung cancer with different epidermal growth factor receptor mutation status
por: Zhong, Xing, et al.
Publicado: (2015)

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
por: Sutani, A, et al.
Publicado: (2006)

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
por: WANG, YUE FENG, et al.
Publicado: (2014)

Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment
por: Chikaishi, Yasuhiro, et al.
Publicado: (2014)

Epidermal growth factor receptor inhibition with Gefitinib does not alter lung responses to mechanical ventilation in fetal, preterm lambs
por: Kothe, T. Brett, et al.
Publicado: (2018)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma: A Case-Control Study()()
por: Zhao, Nan-Jie, et al.
Publicado: (2014)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
por: Patel, Nishant, et al.
Publicado: (2017)

Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo
por: Li, Tao, et al.
Publicado: (2021)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
por: Chen, Minjiang, et al.
Publicado: (2019)

Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib
por: Copps, Beatrice, et al.
Publicado: (2020)

Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer
por: Tian, Hong-Xia, et al.
Publicado: (2017)

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
por: Velazquez, Ana I., et al.
Publicado: (2020)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
por: Harrison, Peter T., et al.
Publicado: (2020)

Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
por: Zhao, Wei, et al.
Publicado: (2022)

Comparative Proteomics Analysis Reveals the Reversal Effect of Cryptotanshinone on Gefitinib-Resistant Cells in Epidermal Growth Factor Receptor-Mutant Lung Cancer
por: Cai, Peiheng, et al.
Publicado: (2022)

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
por: Li, Xuefei, et al.
Publicado: (2014)

Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma
por: Lu, Chao-Wen, et al.
Publicado: (2023)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
por: Tamura, K, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_f0is4iug8areodftjhs7hupus6